---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-007832"
form_type: "8-K"
ticker: "GKOS"
cik: "0001192448"
company_name: "GLAUKOS Corp"
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T00:21:09.901262+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Glaukos Q1 net sales rise 9% to $73.9M; guides 2023 sales up; GAAP net loss widens to $34.6M

## Summary
- Q1 2023 net sales $73.9M (+9% YoY); glaucoma $56.2M (+9%), corneal health $17.7M (+10%).
- GAAP net loss $34.6M ($0.72 loss per share) vs net income $5.4M ($0.11) in Q1 2022.
- Non-GAAP net loss $28.4M ($0.59) vs prior-year non-GAAP net loss $18.1M ($0.38).
- Raised 2023 net sales guidance to $295-300M from $290-295M.
- Operating expenses increased sharply: SG&A +22%, R&D +31%; ended Q1 with $325M cash.

## SEC filing metadata
- accession: 0001558370-23-007832
- form_type: 8-K
- ticker: GKOS
- cik: 0001192448
- company_name: GLAUKOS Corp
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1192448/000155837023007832/0001558370-23-007832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1192448/000155837023007832/gkos-20230503x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-007832
- JSON: https://secwatch.observer/filing/0001558370-23-007832.json
- Plain text: https://secwatch.observer/filing/0001558370-23-007832.txt

## Key facts
- Earnings Releases
  GLAUKOS Corp reported the first quarter ended March 31, 2023 results: revenue $73.9 million, net income $34.6 million, EPS ($0.72) per diluted share. Guidance raised.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $73.9 million
  - Net income: $34.6 million
  - EPS: ($0.72) per diluted share
  - Guidance: raised
  - Result: reported results
  source text: of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2023. Key highlights include: ● Net sales of $73.9 million in Q1 2023 increased 9% year-over-year on a reported basis and 11% year-over-year on a constant currency basis. ● Glaucoma net sales of $56.2 million in Q1 2023 increased 9%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1192448/000155837023007832/0001558370-23-007832-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.